<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="loc_ifrs-full_CashOutflowForLeases_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DividendsPaidClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-full_Equity_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="loc_ifrs-full_FinanceIncomeCost_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit" xlink:label="loc_ifrs-full_GrossProfit_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_18"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_19"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_20"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_21"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_22"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_23"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_24"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_25"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_26"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition" xlink:label="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_27"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_DisclosureOfDistributionExpenses" xlink:label="loc_lavipharm_DisclosureOfDistributionExpenses_28"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_GainLossFromDerecognitionOfSubsidiaries" xlink:label="loc_lavipharm_GainLossFromDerecognitionOfSubsidiaries_29"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_OtherTransactionsBetweenEquity" xlink:label="loc_lavipharm_OtherTransactionsBetweenEquity_30"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_OtherTransactionsBetweenEquity" xlink:label="loc_lavipharm_OtherTransactionsBetweenEquity_31"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState" xlink:label="loc_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_32"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState" xlink:label="loc_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_33"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets" xlink:label="loc_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_34"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets" xlink:label="loc_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_35"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ProfitLossBeforeTaxContinuingOperations" xlink:label="loc_lavipharm_ProfitLossBeforeTaxContinuingOperations_36"/>
    <loc xlink:type="locator" xlink:href="213800USC69CRPRGWJ15-2025-12-31.xsd#lavipharm_ValuationGreekGovernmentBonds" xlink:label="loc_lavipharm_ValuationGreekGovernmentBonds_37"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome_0" xml:lang="el">Προσαρμογές για χρηματοοικονομικά έσοδα</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty_0" xml:lang="el">Προσαρμογές για κέρδη (ζημίες) από προσαρμογή της εύλογης αξίας, επενδύσεις σε ακίνητα</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_0" xml:lang="el">Ταμειακές ροές από (που χρησιμοποιούνται σε) χρηματοδοτικές δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_0" xml:lang="el">Ταμειακές ροές από (που χρησιμοποιούνται σε) επενδυτικές δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_0" xml:lang="el">Ταμειακές ροές από (που χρησιμοποιούνται σε) λειτουργικές δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations_0" xml:lang="el">Ταμειακές ροές από (που χρησιμοποιούνται σε) δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_CashOutflowForLeases_0" xml:lang="el">Ταμειακές εκροές για μισθώσεις</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_0" xml:lang="el">Μερίσματα καταβληθέντα, που κατατάσσονται ως χρηματοδοτικές δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_Equity_0" xml:lang="el">Υπόλοιπο</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_FinanceIncomeCost_0" xml:lang="el">Συνολικά χρηματοοικονομικά έσοδα (δαπα΄νες)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_GrossProfit_0" xml:lang="el">Μικτό κέρδος</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_0" xml:lang="el">Καταβληθέντες φόροι εισοδήματος (επιστροφή), που έχουν ταξινομηθεί ως λειτουργικές δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_0" xml:lang="el">Έξοδα (έσοδα) φόρου</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0" xml:lang="el">Αύξηση (μείωση) ταμειακών διαθεσίμων και ταμειακών ισοδυνάμων μετά την επίπτωση των μεταβολών στις συναλλαγματικές ισοτιμίες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_0" xml:lang="el">Καταβληθέντες τόκοι, που έχουν ταξινομηθεί ως λειτουργικές δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_0" xml:lang="el">Αγορά ενσώματων παγίων, άυλων περιουσιακών στοιχείων πλην της υπεραξίας, επενδύσεων σε ακίνητα και άλλων μη κυκλοφορούντων περιουσιακών στοιχείων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_0" xml:lang="el">Αποπληρωμές δανειοληπτικών πράξεων, που κατατάσσονται στις χρηματοδοτικές δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense_0" xml:lang="el">Έξοδα έρευνας και ανάπτυξης</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_1" xml:lang="el">Ταμειακά διαθέσιμα και ταμειακά ισοδύναμα και ταμειακά διαθέσιμα και ταμειακά ισοδύναμα με περιορισμό στο τέλος της περιόδου</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_2" xml:lang="el">Ταμειακά διαθέσιμα και ταμειακά ισοδύναμα και ταμειακά διαθέσιμα και ταμειακά ισοδύναμα με περιορισμό στην αρχή της περιόδου</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_3" xml:lang="el">Ταμειακά διαθέσιμα και ταμειακά ισοδύναμα και ταμειακά διαθέσιμα και ταμειακά ισοδύναμα με περιορισμό</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_1" xml:lang="el">Ταμειακά διαθέσιμα και ισοδύναμα και ταμειακά διαθέσιμα και ισοδύναμα με περιορισμό συνεχιζόμενων &amp; διακοπεισών δραστηριοτήτων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_1" xml:lang="el">Ταμειακά διαθέσιμα και ισοδύναμα και ταμειακά διαθέσιμα και ισοδύναμα με περιορισμό διακοπεισών δραστηριοτήτων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_2" xml:lang="el">Ταμειακά διαθέσιμα και ισοδύναμα και ταμειακά διαθέσιμα και ισοδύναμα με περιορισμό διακοπεισών δραστηριοτήτων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_0" xml:lang="el">Ταμειακά διαθέσιμα και ταμειακά ισοδύναμα και ταμειακά διαθέσιμα και ταμειακά ισοδύναμα με περιορισμό που διαφέρουν από την Κατάσταση Χρηματοοικονομικής Θέσης</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_2" xml:lang="el">Ταμειακά διαθέσιμα και ταμειακά ισοδύναμα και ταμειακά διαθέσιμα και ταμειακά ισοδύναμα με περιορισμό που διαφέρουν από την Κατάσταση Χρηματοοικονομικής Θέσης, στην αρχή της περιόδου</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_3" xml:lang="el">Ταμειακά διαθέσιμα και ταμειακά ισοδύναμα και ταμειακά διαθέσιμα και ταμειακά ισοδύναμα με περιορισμό που διαφέρουν από την Κατάσταση Χρηματοοικονομικής Θέσης</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_DisclosureOfDistributionExpenses_1" xml:lang="el">Γνωστοποίηση εξόδων διάθεσης</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_GainLossFromDerecognitionOfSubsidiaries_1" xml:lang="el">Κέρδη απο εκκαθάριση Θυγατρικής</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_OtherTransactionsBetweenEquity_0" xml:lang="el">Λοιπές συναλλαγές μεταξ΄ύ των ιδίων κεφαλαίων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_OtherTransactionsBetweenEquity_2" xml:lang="el">Λοιπές συναλλαγές</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_1" xml:lang="el">Καταβολές για δανειοληπτικές πράξεις με Ελ. Δημόσιο.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_1" xml:lang="el">Εισροές από δανειοληπτικές πράξεις με Ελ. Δημόσιο</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_0" xml:lang="el">Εισπράξεις από πώληση μέσω sales and leaseback ενσώματων πάγιων περιουσιακών στοιχείων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_2" xml:lang="el">Εισπράξεις από πώληση μέσω sales and leaseback ενσώματων πάγιων περιουσιακών στοιχείων</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_ProfitLossBeforeTaxContinuingOperations_1" xml:lang="el">Κέρδη / (Ζημιές) προ φόρων από συνεχιζόμενες δραστηριότητες</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_lavipharm_ValuationGreekGovernmentBonds_1" xml:lang="el">Αποτίμηση Ομολόγων Ελληνικού Δημοσίου</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncome_1" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty_2" xlink:to="lab_ifrs-full_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestmentProperty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_3" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_4" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_5" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_6" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases_7" xlink:to="lab_ifrs-full_CashOutflowForLeases_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_8" xlink:to="lab_ifrs-full_DividendsPaidClassifiedAsFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity_9" xlink:to="lab_ifrs-full_Equity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeCost_10" xlink:to="lab_ifrs-full_FinanceIncomeCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossProfit_11" xlink:to="lab_ifrs-full_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_12" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_13" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_14" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestPaidClassifiedAsOperatingActivities_15" xlink:to="lab_ifrs-full_InterestPaidClassifiedAsOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_16" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_17" xlink:to="lab_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_18" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_19" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_20" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_21" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_22" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromContinuingAndDiscontinuedOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_23" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_24" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsFromDiscontinuedOperations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_25" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_26" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_27" xlink:to="lab_lavipharm_CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsIfDifferentFromTheStatementOfFinancialPosition_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_DisclosureOfDistributionExpenses_28" xlink:to="lab_lavipharm_DisclosureOfDistributionExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_GainLossFromDerecognitionOfSubsidiaries_29" xlink:to="lab_lavipharm_GainLossFromDerecognitionOfSubsidiaries_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_OtherTransactionsBetweenEquity_30" xlink:to="lab_lavipharm_OtherTransactionsBetweenEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_OtherTransactionsBetweenEquity_31" xlink:to="lab_lavipharm_OtherTransactionsBetweenEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_32" xlink:to="lab_lavipharm_PaymentsTowardsBorrowingsClassifiedAsFinancingActivitiesGreekState_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_33" xlink:to="lab_lavipharm_ProceedsFromBorrowingsClassifiedAsFinancingActivitiesGreekState_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_34" xlink:to="lab_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_35" xlink:to="lab_lavipharm_ProceedsFromSaleAndLeasebackOfTangibleAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ProfitLossBeforeTaxContinuingOperations_36" xlink:to="lab_lavipharm_ProfitLossBeforeTaxContinuingOperations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lavipharm_ValuationGreekGovernmentBonds_37" xlink:to="lab_lavipharm_ValuationGreekGovernmentBonds_1"/>
  </labelLink>
</linkbase>